Salivary Gland Regeneration Models: Current Concepts and Clinical Implications

Abstract

Salivary gland dysfunction, whether due to autoimmune disease, radiation therapy, or other etiologies, is a significant clinical problem resulting in xerostomia, impaired oral health, and reduced quality of life. In recent years, a surge of research has been directed at developing regeneration models to restore glandular function. This review comprehensively examines the latest in salivary gland regeneration models, including cellular, tissue engineering, and organoid-based approaches, with a focus on their scientific basis, clinical relevance, and translational potential. Recent advances, mechanisms of action, and guideline recommendations are also discussed, providing healthcare professionals with an up-to-date reference for clinical practice and future research.

Introduction

The loss of salivary gland function is a debilitating condition commonly encountered in patients with Sjögren's syndrome, those undergoing head and neck radiation, and individuals with systemic diseases. Traditional management has centered around symptomatic relief, but recent developments in regenerative medicine offer hope for true functional restoration. Salivary gland regeneration models employ a variety of strategies, from stem cell transplantation to bioengineered scaffolds and organoid cultures, seeking to recapitulate the gland's intricate architecture and secretory capacity. Understanding these models is crucial for clinicians, researchers, and medical educators aiming to translate benchside innovations to bedside solutions.

Epidemiology / Disease Burden

Salivary gland hypofunction affects millions globally, with a particularly high prevalence among cancer survivors and patients with autoimmune disorders. The incidence of radiation-induced xerostomia in head and neck cancer patients can exceed 60%, while Sjögren's syndrome, a prototypical autoimmune cause, has a prevalence of 0.1–4.8% depending on the population studied. The resultant decrease in salivary flow predisposes individuals to dental caries, oral infections, dysphagia, and diminished nutritional status, underscoring the need for innovative regenerative strategies.

Pathophysiology

Salivary glands are composed of acinar, ductal, and myoepithelial cells arranged in a highly organized manner to facilitate saliva production and secretion. Damage to any component, whether by autoimmune attack, irradiation, or obstructive processes, disrupts this architecture and impairs function. The pathophysiology involves acinar cell loss, ductal atrophy, fibrosis, and altered cellular signaling. Regeneration models aim to restore glandular integrity by replacing lost cells, reestablishing ductal networks, and reactivating endogenous repair pathways, often leveraging the plasticity of stem/progenitor cells and the instructive role of the glandular microenvironment.

Risk Factors

The primary risk factors for salivary gland dysfunction include exposure to head and neck radiation, autoimmune diseases (notably Sjögren's syndrome), chronic infections, obstructive sialadenitis, and certain medications (e.g., anticholinergics, antihypertensives). Age-related atrophy and systemic conditions such as diabetes mellitus also contribute to reduced glandular reserve, compounding the risk in vulnerable populations.

Clinical Features

Patients with salivary gland hypofunction typically present with xerostomia (dry mouth), dysgeusia (altered taste), difficulty in mastication and swallowing, increased dental caries, oral candidiasis, and mucosal ulcerations. Chronic cases are often complicated by sialadenitis and glandular swelling. The impact on oral comfort, nutrition, and overall health is profound, necessitating effective and durable therapeutic interventions.

Diagnosis

Diagnosis of salivary gland dysfunction is multi-faceted, involving clinical assessment, sialometry (measurement of salivary flow), imaging (ultrasound, MRI, sialography), and, when indicated, histopathological examination via labial gland biopsy. Functional assays assess the residual secretory capacity, while autoantibody profiling aids in the diagnosis of autoimmune etiologies. Emerging biomarkers and imaging modalities are enhancing the precision of glandular assessment and monitoring of regenerative outcomes.

Treatment & Management

Conventional management prioritizes symptom control through saliva substitutes, sialogogues (e.g., pilocarpine), meticulous oral hygiene, and management of complications. However, these approaches do not restore native gland function. Regenerative therapies, including transplantation of stem/progenitor cells, gene therapy, and scaffold-based tissue engineering, are being actively explored. Animal models and early clinical trials have demonstrated partial restoration of function and glandular structure, though challenges remain in achieving full integration and long-term efficacy.

Recent Advances / Emerging Therapies

Recent years have witnessed remarkable progress in salivary gland regeneration models. Organoid technology now enables the ex vivo culture of mini-glands from patient-derived cells, providing platforms for disease modeling and cell therapy. Advances in 3D bioprinting and synthetic scaffolds have allowed for the recreation of complex glandular architecture. Genetic reprogramming of resident ductal or myoepithelial cells offers another promising avenue, while paracrine signaling modulation is being leveraged to enhance endogenous repair. Early-phase clinical studies have reported promising results with autologous cell transplantation in radiation-induced xerostomia, highlighting the translational potential of these models.

Guideline Recommendations

Current clinical guidelines still emphasize symptomatic management, but there is a growing consensus on the need to integrate regenerative approaches into therapeutic algorithms, particularly for patients with irreversible glandular loss. The American Academy of Otolaryngology–Head and Neck Surgery and the European Salivary Gland Society recommend participation in clinical trials evaluating regenerative therapies, with careful patient selection, standardized outcome measures, and long-term follow-up. Multidisciplinary collaboration is essential to ensure safe and effective translation of these innovations to routine care.

Conclusion

Salivary gland regeneration models represent a paradigm shift in the management of glandular dysfunction. While significant challenges remain—particularly in achieving functional integration and scalability—ongoing advances in stem cell biology, tissue engineering, and translational research are rapidly bringing these therapies closer to clinical reality. Continued collaboration between basic scientists, clinicians, and regulatory bodies will be pivotal in establishing safe, effective, and widely accessible regenerative treatments for patients suffering from salivary gland disorders.